May 20 (Reuters) - Tourmaline Bio Inc TRML.O:
TOURMALINE BIO ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE ONGOING PHASE 2 TRANQUILITY TRIAL EVALUATING PACIBEKITUG IN PATIENTS WITH ELEVATED HIGH-SENSITIVITY C-REACTIVE PROTEIN AND CHRONIC KIDNEY DISEASE
TOURMALINE BIO INC - PACIBEKITUG ACHIEVES SIGNIFICANT HS-CRP REDUCTIONS THROUGH DAY 90
Source text: ID:nGNXb8kycJ
Further company coverage: TRML.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.